MONMOUTH JUNCTION, N.J., Aug. 16 /PRNewswire-FirstCall/ -- Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, Inc. -- (BULLETIN BOARD: CQST) -- announced today that its proprietary, highly versatile chiral-catalyst, C3-TunePhos, is available for commercial-scale shipping on kilogram scale.
C3-TunePhos is the first of the Company’s catalysts available for commercial sale by kilogram. Chiral Quest has begun shipment of the catalyst to large pharmaceutical and fine chemical companies.
“The successful scale-up of production of one of our patented ligands is an important Company milestone,” said Ronald Brandt, CEO of Chiral Quest, Inc. “We have shown that we can successfully tap into the commercial potential of our unique proprietary compounds. This achievement is a significant step in Chiral Quest’s evolution towards being a leading provider of high value technology offering proprietary catalysts, novel building blocks and targets, as well as collaborative synthetic solutions.”
About C3-TunePhos
C3-TunePhos is one of a group of chiral biaryl phosphines with an optimized bite angle. For example, Ruthenium C3-TunePhos complexes can be used to hydrogenate ethyl 4-chloroacetate in a high selectivity (up to 99% enantiomeric excesses), high activity (9 tons per kg of the catalyst) and under mild operating conditions. This reduction product is a key piece for making lipid-lowering agents such as Atorvastatin (Lipitor(TM)). Ruthenium C3-TunePhos complexes can also be used for hydrogenation of alkenes to make chiral cyclic beta-amino acids, and asymmetric hydrogenation of amino ketones to generate a variety of chiral amino alcohols.
About Chiral Quest
Chiral Quest is a research-based life sciences chemistry company that provides chiral products, technology and services to the pharmaceutical and fine chemical industries. The Company develops chemical catalysts and other products used in the synthesis of desired isomers of chiral molecules. For more information, visit http://www.chiralquest.com/.
About VioQuest
VioQuest Pharmaceuticals, Inc. has two operating subsidiaries. Chiral Quest, Inc. is a research-based life sciences chemistry company that provides chiral products, technology and services to the pharmaceutical and fine chemical industries. It develops chemical catalysts and other products used in the synthesis of desired isomers of chiral molecules. VioQuest Drug Development, Inc. is a recently created subsidiary which intends to acquire, develop and commercialize human therapeutics.
For more information, visit http://www.chiralquest.com/. Forward-Looking Statements:
This press release contains forward-looking statements that involve risks and uncertainties that could cause Chiral Quest’s actual results and experience to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Chiral Quest’s research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Chiral Quest assumes no obligation and does not intend to update these forward-looking statements.
Chiral Quest, Inc.
CONTACT: Brian Lenz of Chiral Quest, Inc., +1-732-274-0399; or ThomasFechtner, Investor Relations of The Trout Group, +1-212-477-9007 ext. 31
Web site: http://www.chiralquest.com/
